Physician profile
Saba Afraz
NPI 1972900355
$739.21
in general payments reported to CMS, 2019-2025
10 companies · $36.70 in 2025
The $36.70 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $86.09 · 2021: $233 · 2022: $325 · 2023: $44.63 · 2024: $14.06 · 2025: $36.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $95.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $95.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $221.45 | 2020-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.18 | 2021-2023 | Jardiance |
| Pfizer INC. | $105.99 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $75.47 | 2022 | |
| Novartis Pharmaceuticals Corporation | $46.43 | 2021-2022 | |
| Gilead Sciences, INC. | $37.85 | 2021-2022 | |
| Abbvie INC. | $30.41 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $26.73 | 2020-2021 | |
| Amgen INC. | $22.06 | 2025 | Repatha |
| Glaxosmithkline, LLC. | $14.64 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saba Afraz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.